Turning Injectables Into Pills:
Rani is developing a novel approach for the oral delivery of biologics, a $170BN market of injectable drugs used to treat chronic diseases such as diabetes and rheumatoid arthritis. We've successfully delivered 2 commercially available drugs in pre-clinical trials with 100% equivalence to injection.
Seasoned team with 15 exits: $380M invested and $1.8B returned to investorsJune, 2015
Over 50 patents filed in US and abroad with 11 patents issuedJune, 2015
Successfully delivered 2 commercially available drugs in preclinical trials with 100% equivalence to injectionsJune, 2015
$20M invested by Novartis, Google Ventures, Stevanato Group, InCube Ventures and VentureHealthJune, 2015
Unprecedented pre-clinical resultsJune, 2015
Closed first option/license dealJune, 2015